Table 5

Rhinitis symptom assessment outcomes in adults with seasonal allergic rhinitis

Study
Sample size
Trial duration
Age
%
female
Treatment ATreatment BPhysician-rated global evaluation of improvement (% pts)% Change in total symptom score
McArthur, 1994
N=77
3 weeks
27
years
51%
Budesonide
200 mcg
Beclomethasone
200 mcg
Noticeably, very or total effective: 85% compared with 82%, NSNR
Langrick, 1984
N=60
7 weeks
66.7
years
37.5%
Flunisolide
200 mcg
Beclomethasone
400 mcg
Total improvement: 29% compared with 34%, NSNR
Welsh, 1987
N=100
6 weeks
28
years
33%
Flunisolide
200 mcg
Beclomethasone
336 mcg
Substantial (patient-rated): 80% compared with 75%, NSTotal hay fever score: +13.1% compared with +96.4%, NS
Bronsky, 1987
N=151
4 weeks
29
years
52%
Flunisolide
200 or 300 mcg
Beclomethasone
168 or 336 mcg
Major improvement: 27% compared with 38% compared with 40% compared with 46%, NSNR
Ratner, 1992
N=136
2 weeks
44
years
62%
Fluticasone
200 mcg
Beclomethasone
336 mcg
Significant or moderate: 53% compared with 59%, NSNR
Laforce, 1994
N=238
4 weeks
24
years
29%
Fluticasone
200 mg BID or QD
Beclomethasone
336 mcg
Significant or moderate: 65% compared with 70% compared with 65%, NSTNSS: −43% compared with −53% compared with −32%, NS
Hebert, 1996
N=477
4 weeks
32
years
8.5%
Mometasone
100 or 200 mcg
Beclomethasone
400 mcg
Complete/marked relief: 77% compared with 79% compared with 74%, NSTNSS: −53% compared with −59% compared with −59%; NS
Lumry, 2003
N=147
3 weeks
37
years
51%
Triamcinolone
AQ 220 mcg
Beclomethasone
336 mcg
Greatly or somewhat improved: 78.4% compared with 87%, NSNasal Index: −42.9% compared with −45.9%, NS
Stern, 1997
N=635
4–6 weeks
Age NR
51%
Budesonide
128 or 256 mcg
Fluticasone
200 mcg
Substantial or total control - patients: 85% compared with 88% compared with 82%, NSCombined nasal symptom scorea: −26.5% compared with −29.4% compared with −29.4%, NS
Kaiser, 2004
N=295
3 weeks
31.6
years
62%
Triamcinolone
AQ 220 mcg
Fluticasone
200 mcg
NRTNSS: −48% compared with −49.7%, NS
Gross, 2002
N=352
3 weeks
38.8
years
66.5%
Triamcinolone
AQ
220 mcg
Fluticasone
200 mcg
NRTNSS: −49.4% compared with − 52.7%, NS
Small, 1997
N=233
3 weeks
28
years
52%
Triamcinolone
HFA
220 mcg
Fluticasone
200 mcg
NRRIS**: −55% compared with −60%, NS
Ratner, 1996
N=218
6 weeks
44
years
62%
New flunisolide
200 mcg
Old flunisolide
200 mcg
NRTNSS means: 3.81 compared with 3.55; NS
Greenbaum,
1988
N=122
4 weeks
NR
NR
New flunisolide
200 mcg
Old flunisolide
200 mcg
NRNR
a

Prespecified as primary outcome

From: Results

Cover of Drug Class Review: Nasal Corticosteroids
Drug Class Review: Nasal Corticosteroids: Final Report Update 1 [Internet].
Selover D, Dana T, Smith C, et al.
Portland (OR): Oregon Health & Science University; 2008 Jun.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.